2L
AMED

25 LLC’s Amedisys AMED Stock Holding History

25 LLC’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-7
Closed -$634 – 63
2023
Q2 		$634 Buy
+7
New +$574 ﹤0.01% 363

Other funds holding AMED

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

25 LLC's AMED Position: Q3 2023 in Review

25 LLC sold out of Amedisys (AMED) in Q3 2023, closing a stake of 7 shares — an estimated $634 sold.

25 LLC first reported a position in AMED in Q2 2023 and held it in 1 quarter. The position peaked at $634 in Q2 2023. 286 funds tracked by Wall St. Rank hold AMED as of Q3 2023.

  • 25 LLC reported no remaining Amedisys position as of Q3 2023 after selling out during the quarter.
  • 25 LLC sold 7 Amedisys shares in Q3 2023, an estimated $634.
  • 25 LLC first reported a position in Amedisys in Q2 2023 and held it in 1 quarter.
  • 25 LLC's Amedisys position peaked at $634 in Q2 2023.
  • 286 funds tracked by Wall St. Rank held Amedisys as of Q3 2023.

Based on 25 LLC's 13F filing for Q3 2023, filed 18 Oct 2023.